Seeking Alpha

After coming out of the quiet period, Morgan Stanley initiates Chimerix (CMRX -0.2%) with an...

After coming out of the quiet period, Morgan Stanley initiates Chimerix (CMRX -0.2%) with an Overweight rating and a $26.00 price target. Morgan says the company is developing CMX001, a drug for the treatment of a broad range of dsDNA viruses, which has all the bells and whistles to be a blockbuster with best in disease potential, including having important impact on high acuity points and fulfilling a clear unmet need. Additionally, Cowen starts the shares with an Outperform and Lazard with a Buy.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs